Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Studie van de werkzaamheid en veiligheid PF-06741086 bij volwassen en tienerdeelnemers met ernstige hemofilie A of matig ernstige tot ernstige hemofilie B

23 juli 2026 bijgewerkt door: Pfizer

Een open-label onderzoek bij adolescenten en volwassenen met ernstige (stollingsfactoractiviteit

Behandeling met PF-06741086 zal naar verwachting een klinisch relevant voordeel en/of een belangrijke bijdrage aan de patiëntenzorg aantonen in vergelijking met de huidige behandelingsmethoden voor hemofilie A of B, omdat het anders werkt dan factorvervangende producten en zal werken in de aanwezigheid van remmers . Het potentieel voor eenmaal per week (QW) subcutane (SC) toediening biedt behandelingsopties bij afwezigheid van betrouwbare vasculaire toegang, meer gemak en kan een betere therapietrouw mogelijk maken. Gecombineerd zouden deze eigenschappen moeten resulteren in een vermindering van bloedingsepisodes.

Studie Overzicht

Toestand

Voltooid

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Werkelijk)

188

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Sofia, Bulgarije, 1756
        • National Specialized Hospital for the Active Treatment of Hematological Diseases - EAD, Sofia
      • Stara Zagora, Bulgarije, 6003
        • UMHAT "Prof.Dr. Stoyan Kirkovich"
    • Ontario
      • Hamilton, Ontario, Canada, L8S 4K1
        • McMaster University
      • Hamilton, Ontario, Canada, L8S 4K1
        • McMaster Children's Hospital
      • Hamilton, Ontario, Canada, L8N 3Z5
        • McMaster University Medical Centre - Hamilton Health Sciences
      • Toronto, Ontario, Canada, M5G 1X8
        • The Hospital for Sick Children
      • Beijing, China, 100045
        • Beijing Children's Hospital, Capital Medical University
    • Guangdong
      • Guangzhou, Guangdong, China, 510515
        • Nanfang Hospital, Southern Medical University
    • Guizhou
      • Guiyang, Guizhou, China, 550004
        • The Affiliated Hospital of Guizhou Medical University
    • Jiangxi
      • Nanchang, Jiangxi, China, 306113
        • Jiangxi Provincial People's Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300020
        • Institute of Hematology, Chinese Academy of Medical Sciences
      • Paris, Frankrijk, 75015
        • Hôpital Necker Enfants malades
      • Hong Kong, Hongkong
        • Queen Mary Hospital
      • Hong Kong, Hongkong
        • Prince of Wales Hospital
    • Gujarat
      • Surat, Gujarat, Indië, 395002
        • Nirmal Hospital Pvt, Ltd
    • Maharashtra
      • Pune, Maharashtra, Indië, 411004
        • Sahyadri Super Speciality Hospital
      • Pune, Maharashtra, Indië, 411004
        • Sahyadri Clinical Research And Development Center
    • Tamil Nadu
      • Vellore, Tamil Nadu, Indië, 632004
        • Christian Medical College
      • Perugia, Italië, 06156
        • Università degli Studi di Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria della
    • Milan
      • Milan, Milan, Italië, 20122
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    • RM
      • Roma, RM, Italië, 00161
        • Università degli Studi di Roma "Sapienza"-Policlinico Umberto I
      • Hiroshima, Japan, 734-8551
        • Hiroshima University Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 466-8560
        • Nagoya University Hospital - Transfusion Medicine
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 004-0041
        • Sapporo Tokushukai Hospital
    • Saitama
      • Iruma-gun, Saitama, Japan, 350-0495
        • Saitama Medical University Hospital
      • Zagreb, Kroatië, 10000
        • Klinicki bolnicki centar Zagreb
    • Nuevo León
      • Monterrey, Nuevo León, Mexico, 64460
        • Hospital Universitario "Dr Jose Eleuterio Gonzalez"
    • Yucatán
      • Mérida, Yucatán, Mexico, 97130
        • Centro Multidisciplinario para el Desarrollo Especializado de la Inv. Clínica en Yucatán, S.C.P.
      • Muscat, Oman, 123
        • Sultan Qaboos University Hospital
      • Samara, Rusland, 443079
        • FGBOU VO "Samara State Medical University" of MoH of Russia
      • Jeddah, Saoedi-Arabië, 21589
        • King AbdulAziz University Hospital
      • Riyadh, Saoedi-Arabië
        • King Faisal Specialist Hospital & Research Center
      • Belgrade, Servië, 11000
        • Clinical Center of Serbia
      • Belgrade, Servië, 11000
        • Institute for Mother and Child healthcare "Dr Vukan Cupic"
      • Kragujevac, Servië, 34000
        • Clinical Center Kragujevac
      • Niš, Servië, 18000
        • Clinical Center Niš
      • A Coruña, Spanje, 15006
        • Hospital Universitario A Coruna
      • Barcelona, Spanje, 08035
        • Hospital Universitario Vall d´Hebron
      • Madrid, Spanje, 28046
        • Hospital Universitario La Paz
      • Salamanca, Spanje, 37007
        • Hospital Universitario De Salamanca
      • Zaragoza, Spanje, 50009
        • Hospital Universitario Miguel Servet
      • Taichung, Taiwan, 40705
        • Taichung Veterans General Hospital
    • Changhua County
      • Changhua, Changhua County, Taiwan, 500
        • Changhua Christian Hospital
      • Adana, Turkije (Türkiye), 01130
        • Acibadem Adana Hospital
      • Ankara, Turkije (Türkiye), 06230
        • Hacettepe University Medical Faculty
      • Ankara, Turkije (Türkiye), 06500
        • Gazi University Health Research and Practice Center Gazi Hospital
      • Antalya, Turkije (Türkiye), 07060
        • Akdeniz University Medical Faculty
      • Gaziantep, Turkije (Türkiye), 27310
        • Gaziantep University Sahinbey Research and Training Hospital
      • Istanbul, Turkije (Türkiye), 34093
        • Istanbul University Oncology Institute
      • Izmir, Turkije (Türkiye), 35040
        • Ege University Medical Faculty
      • Izmir, Turkije (Türkiye), 35210
        • Dr. Behcet Uz Child Diseases Surgery Education and Research Hospital
      • Kayseri, Turkije (Türkiye), 38039
        • Erciyes University Medical Faculty
      • Samsun, Turkije (Türkiye), 55280
        • Ondokuz Mayıs University Medical Faculty
      • Trabzon, Turkije (Türkiye), 61080
        • Karadeniz Technical University Medical Faculty
    • Florida
      • Tampa, Florida, Verenigde Staten, 33612
        • USF Health Morsani Center for Advanced Healthcare
    • Iowa
      • Iowa City, Iowa, Verenigde Staten, 52242
        • University of Iowa
    • New York
      • New Hyde Park, New York, Verenigde Staten, 11040
        • Northwell Health HTC
    • Washington
      • Seattle, Washington, Verenigde Staten, 98101
        • Washington Institute for Coagulation
      • Daegu, Zuid -Korea, 41944
        • Kyungpook National University Hospital
      • Seoul, Zuid -Korea, 03722
        • Severance Hospital, Yonsei University Health System
      • Seoul, Zuid -Korea, 05278
        • Kyung Hee University Hospital at Gangdong
    • Gauteng
      • Johannesburg, Gauteng, Zuid-Afrika, 2193
        • Charlotte Maxeke Johannesburg Academic Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

12 jaar tot 74 jaar (Kind, Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusiecriteria

  • Deelnemers met de diagnose ernstige hemofilie A of matig ernstige tot ernstige hemofilie B met een minimumgewicht van 35 kg bij screening.
  • Deelnemer of wettelijk gemachtigde vertegenwoordiger, of de verzorger van de deelnemer die in staat is om ondertekende geïnformeerde toestemming te geven (of kleine instemming, indien van toepassing).

Deelnemers die zijn ingeschreven in het niet-remmercohort moeten ook aan de volgende criteria voldoen:

  • Geen detecteerbare of gedocumenteerde geschiedenis van remmers
  • Deelnemers aan FVIII/FIX-routinematige profylaxe die ten minste 80% naleving van het geplande profylaxeregime hebben aangetoond gedurende 6 maanden voorafgaand aan inschrijving en die bereid zijn om routinematige profylaxebehandeling met FVIII/FIX-vervanging te blijven ontvangen tijdens de observatiefase.
  • Deelnemers met een behandelingsregime op aanvraag met ≥6 acute bloedingsepisodes (spontaan of traumatisch) waarvoor infusie van stollingsfactor nodig was gedurende de 6 maanden voorafgaand aan inschrijving en die bereid waren om behandeling op aanvraag te blijven ontvangen tijdens de observatiefase.

Deelnemers die zijn ingeschreven in het remmercohort moeten ook aan de volgende criteria voldoen:

  • Documentatie van huidige remmer met hoge titer (≥5 BU/ml) of huidige remmer met lage titer (<5 BU/ml) refractair voor FVIII- of FIX-vervanging en met FVIII- of FIX-herstel <60% van verwacht in de afgelopen 6 maanden voorafgaand aan opname in de observatiefase
  • Hemofilie A-deelnemers met een behandelschema op verzoek met ≥6 bloedingsepisodes of hemofilie B-deelnemers met ≥4 bloedingsepisodes (spontaan of traumatisch) waarvoor behandeling met een bypass-factor noodzakelijk was gedurende de 6 maanden voorafgaand aan opname in de observatiefase en die bereid zijn door te gaan met het ontvangen van -vraag om behandeling tijdens de observatiefase.
  • Deelnemers die gedocumenteerde remmers hebben terwijl ze factorvervangende therapie ondergaan, maar die niet voldoen aan de kwantitatieve criteria voor remmers beschreven in de voorgaande bullet op het moment van de screening (bijv. deelnemer met een eerder gedocumenteerde hoge-titerremmer (≥5 BU/ml) en wiens toestand hernieuwde provocatie met FVIII- of FIX-vervanging uitsluit) kan per geval worden overwogen om in aanmerking te komen met voorafgaande toestemming van de Pfizer Medical Monitor
  • Deelnemers die voldoen aan de hierboven vermelde bloedingscriteria en die routinematige profylaxe ondergaan (gedefinieerd als behandeling door middel van IV-injectie van bypass-factor om bloeding te voorkomen) en die hebben aangetoond dat ten minste 80% het geplande profylaxeregime volgt gedurende de 6 maanden voorafgaand aan inschrijving, kunnen worden van geval tot geval overwogen om in aanmerking te komen, met bespreking en instemming van de medische monitor van Pfizer.

Uitsluitingscriteria

  • Eerdere of huidige behandeling voor en/of voorgeschiedenis van coronaire hartziekten, veneuze of arteriële trombose of ischemische ziekte
  • Bekende geplande chirurgische ingreep tijdens de geplande studieperiode.
  • Bekend hemostatisch defect anders dan hemofilie A of B.
  • Abnormale nier- of leverfunctie
  • Huidige onstabiele lever- of galziekte
  • Abnormale hematologische parameters
  • Andere acute of chronische medische of psychiatrische aandoening of laboratoriumafwijking die het risico kan verhogen dat gepaard gaat met deelname aan de studie of toediening van onderzoeksproducten of die de interpretatie van onderzoeksresultaten kan verstoren en, naar het oordeel van de onderzoeker,
  • Huidige routinematige profylaxe met bypassing agent of non-coagulatie non-factor substitutietherapie, of enige eerdere behandeling met een gentherapieproduct voor de behandeling van hemofilie geval per geval bekeken).
  • Regelmatige, gelijktijdige therapie met immunomodulerende geneesmiddelen

    - Lopend of gepland gebruik van immuuntolerantie-inductie tijdens de observatiefase of actieve behandelingsfase, of profylaxe met FVIII- of FIX-vervanging op enig moment na aanvang van de behandeling met studie-interventie tijdens de actieve behandelingsfase

  • Eerdere blootstelling aan PF 06741086 tijdens deelname aan onderzoeken B7841002 en B7841003.
  • Deelname aan andere onderzoeken met onderzoeksgeneesmiddelen of onderzoeksvaccins binnen 30 dagen (of zoals bepaald door lokale vereisten) of 5 halfwaardetijden voorafgaand aan het begin van het onderzoek en/of tijdens deelname aan het onderzoek.
  • Aantal CD4-cellen ≤200/uL indien humaan immunodeficiëntievirus (HIV)-positief
  • Screening-ECG dat klinisch relevante afwijkingen aantoont die van invloed kunnen zijn op de veiligheid van de deelnemer of de interpretatie van onderzoeksresultaten.
  • Personen met overgevoeligheid of een allergische reactie op hamstereiwit of andere componenten van de onderzoeksinterventie.
  • Medewerkers van de locatie van de onderzoeker die direct betrokken zijn bij de uitvoering van het onderzoek en hun gezinsleden, medewerkers van de locatie die anderszins onder toezicht staan ​​van de onderzoeker, of deelnemers die Pfizer-medewerkers zijn, met inbegrip van hun familieleden, die direct betrokken zijn bij de uitvoering van het onderzoek.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Crossover-opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: PF-06741086
Deelnemers zullen worden toegewezen aan behandeling met PF-06741086 na een observatiefase van 6 maanden op hun huidige hemofilieregime.
300 milligram (mg) subcutane (sc) oplaaddosis gevolgd door 150 mg sq eenmaal per week (qw). 300 mg sc qw wordt voorgeschreven aan deelnemers die voldoen aan de criteria voor dosisescalatie.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Model-Based Annualized Bleeding Rate (ABR) of Treated Bleeding Events: Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR is defined as number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication). A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR is defined as number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication). A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With RP at OP)
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR is defined as number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication). A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Number of Participants With Adverse Events (AEs): Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious AEs and all other AEs.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Serious Adverse Events (SAEs): Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
AE: any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE: any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Thrombotic Events: Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Thrombotic events are when a blood clot (thrombus) forms in a blood vessel in the arm, leg, lung, or head and can be life-threatening. A thrombus can occur in veins (venous thrombosis) or arteries (arterial thrombosis).
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Thrombotic Microangiopathy: Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Thrombotic microangiopathy: pathological state where micro-vessels are occluded by platelet rich thrombi leading to thrombocytopenia (low platelets) and microangiopathic haemolytic anaemia (red blood cell destruction) and potential end organ damage.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Disseminated Intravascular Coagulation/ Consumption Coagulopathy: Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Disseminated intravascular coagulation is characterized by widespread clotting in small blood vessels, and consumption of platelets and clotting factors by the clots, leading to bleeding.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF- 06741086: Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: During prophylaxis treatment in ATP (12 months)
ADA positive: A participant with >=1 treatment induced or treatment-boosted ADA response. NAb positive: An ADA positive participant with >=1 treatment induced or treatment boosted NAb response.
During prophylaxis treatment in ATP (12 months)
Number of Participants With Transient and Persistent ADA and NAb Against PF-06741086: Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: During prophylaxis treatment in ATP (12 months)
Persistent ADA: participant with treatment-induced or treatment-boosted ADA detected at 2 or more times during treatment including any follow-up, where first and last ADA positive samples separated by >=16 weeks. Transient ADA: treatment-induced or treatment-boosted ADA detected at only 1 time during treatment or follow-up. Persistent NAb: NAb-positive participant with first and last positive NAb samples detected >=16 weeks posttreatment, irrespective of any negative samples in between. Transient NAb: NAb-positive participant with (1) treatment-induced/treatment-boosted NAb sample detected at only 1 time posttreatment or (2) treatment-induced/treatment-boosted NAb samples detected at 2 or more times where first and last positive samples separated by <16 weeks, and participant's last sample was NAb or ADA negative.
During prophylaxis treatment in ATP (12 months)
Number of Participants With Injection Site Reactions (ISRs): Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: During prophylaxis treatment in ATP (12 months)
ISR included: injection site haematoma, injection site pain, injection site bruising, injection site erythema, injection site induration, injection site oedema, Injection site pruritus and Injection site swelling. ISR graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 where grade 1: tenderness with or without associated symptoms (warmth, erythema, itching), grade 2: pain, lipodystrophy, edema, phlebitis, grade 3: ulceration or necrosis, severe tissue damage, operative intervention indicated, grade 4: life-threatening consequences, urgent intervention indicated and grade 5: death. In this outcome measure only categories with non-zero values reported.
During prophylaxis treatment in ATP (12 months)
Number of Participants With Clinically Significant Changes in Physical Examinations: Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Physical examination included assessments of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Height and weight were also measured and recorded. Clinical significance in physical examinations was determined by investigator.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Clinically Significant Changes in Vital Signs: Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Vital signs included temperature, pulse rate, respiratory rate, and blood pressure. Blood pressure and pulse rate were measured in a supine position using completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Respiratory rate was measured by observing and counting the respirations of the participant for 30 seconds and multiplied by 2. Clinical significance of vital signs was determined by investigator.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters: Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Hematology included: hemoglobin; leukocytes; neutrophils; and platelets. Chemistry included: potassium; aspartate aminotransferase; creatinine; alkaline phosphatase; total bilirubin; albumin; calcium corrected, estimated decreased; sodium; and calcium. Clinical significance of laboratory parameters was determined by investigator.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Severe/ Systematic Hypersensitivity and Anaphylactic Reactions: Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: During prophylaxis treatment in ATP (12 months)
Systemic hypersensitivity is a complex immune response where the immune system reacts excessively to an antigen, often leading to severe allergic reactions, including widespread symptoms (which may affect multiple organs), such as rash, swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, dizziness, fainting, fast heartbeat, pounding in your chest or sweating. Anaphylaxis is a severe, potentially fatal, systemic allergic reaction that occurs suddenly after contact with an allergy causing substance.
During prophylaxis treatment in ATP (12 months)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Model-Based ABR of Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of the following: pain or an unusual sensation in the joint, palpable swelling, and warmth of the skin over the joint. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Spontaneous Bleeds: Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as the number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, the days on treatment ended at the last dosing date + 6 days. Spontaneous bleed: Bleeding for no apparent/known reason particularly into the joints, muscles, and soft tissues. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Target Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Target joint: a major joint into which repeated bleeds occurred. Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of following: pain or unusual sensation in joint, palpable swelling, and warmth of the skin over joint. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Total Bleeds: Inhibitor and Non-Inhibitor Cohort
Tijdsspanne: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If participant did not complete treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication). Untreated bleed: If a bleed was untreated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication), it was considered as an untreated bleed. Total bleeds: Treated bleeds + untreated bleeds. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Change From Baseline in Hemophilia Joint Health Score (HJHS) at Month 6: Non-Inhibitor Cohort
Tijdsspanne: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score. Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]). Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg. HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4). The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in HJHS at Month 6: Inhibitor Cohort
Tijdsspanne: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score. Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]). Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg. HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4). The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) Total Score and Physical Health Domain at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Tijdsspanne: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia. It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality. All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Haem-A-QoL Total Score and Physical Health Domain at Month 6: Inhibitor Cohort, Participants >=17 Years
Tijdsspanne: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia. It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality. All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Hemophilia Quality of Life Questionnaire for Children (Haemo-QoL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Tijdsspanne: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia. It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship. All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Haemo-QoL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Tijdsspanne: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia. It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship. All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Hemophilia Activities List (HAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Tijdsspanne: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age). The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in HAL Total Score at Month 6: Inhibitor Cohort, Participants >=17 Years
Tijdsspanne: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age). The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Pediatric Hemophilia Activities List (pedHAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Tijdsspanne: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age). The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in pedHAL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Tijdsspanne: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age). The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Patient Global Impression of Change-Hemophilia (PGIC-H) at Month 6: Non-Inhibitor Cohort
Tijdsspanne: Month 6
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
Month 6
PGIC-H at Month 6: Inhibitor Cohort
Tijdsspanne: Month 6
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
Month 6
Change From Baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Index and VAS Scores at Month 6: Non-Inhibitor Cohort
Tijdsspanne: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS). EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems). Responses to 5 dimensions comprised health state index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it. EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states. The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in EQ-5D-5L Index and VAS Scores at Month 6: Inhibitor Cohort
Tijdsspanne: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS). EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems). Responses to 5 dimensions comprised health state index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it. EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states. The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: Pfizer CT.gov Call Center, Pfizer

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

9 maart 2020

Primaire voltooiing (Werkelijk)

29 april 2025

Studie voltooiing (Werkelijk)

29 april 2025

Studieregistratiedata

Eerst ingediend

2 mei 2019

Eerst ingediend dat voldeed aan de QC-criteria

2 mei 2019

Eerst geplaatst (Werkelijk)

6 mei 2019

Updates van studierecords

Laatste update geplaatst (Werkelijk)

14 augustus 2026

Laatste update ingediend die voldeed aan QC-criteria

23 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Pfizer zal toegang verlenen tot gegevens van individuele geanonimiseerde deelnemers en gerelateerde onderzoeksdocumenten (bijv. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) op verzoek van gekwalificeerde onderzoekers en onder voorbehoud van bepaalde criteria, voorwaarden en uitzonderingen. Meer details over Pfizer's criteria voor het delen van gegevens en het proces voor het aanvragen van toegang zijn te vinden op: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren